Endometrial biopsy is a reliable test, but not a perfect one. When a Pipelle biopsy (the most common office version) detects something abnormal, it’s right about 97.6% of the time. The catch is what it can miss: blind sampling, where the doctor can’t see inside the uterus during the procedure, has been reported to miss up to 62.5% of endometrial pathologies, particularly small or localized growths. So a positive result is highly trustworthy, but a negative result doesn’t always rule everything out.
Overall Accuracy by the Numbers
The Pipelle biopsy, a thin flexible tube inserted through the cervix to suction a tissue sample, is the standard office procedure. In a study comparing Pipelle results directly against the more thorough dilation and curettage (D&C), the two methods agreed 97.6% of the time. The Pipelle showed a sensitivity of 94.1%, meaning it correctly identified abnormal tissue in about 94 out of 100 cases where disease was present. Specificity was even higher at 99.8%, so false alarms are extremely rare.
These numbers look reassuring, and for widespread disease that affects large portions of the uterine lining, they are. The problem emerges with focal lesions: polyps, small areas of precancerous change, or early-stage cancers that occupy only a small patch of tissue. Because the Pipelle samples blindly, it can only collect tissue from wherever the tube happens to land. If the abnormal area is small and the tube misses it, the biopsy comes back normal even though something is there.
What Blind Sampling Can Miss
The term “blind sampling” means the doctor is collecting tissue without being able to see the inside of the uterus. Both Pipelle biopsy and traditional D&C share this limitation. Research has shown that non-visualized endometrial sampling can miss up to 62.5% of endometrial pathologies. That figure includes polyps, localized hyperplasia, and early cancers that haven’t spread across the entire lining.
This is why persistent symptoms matter. If you continue to have abnormal bleeding after a normal biopsy result, clinical guidelines recommend hysteroscopy, a procedure where a small camera is inserted into the uterus so the doctor can see the lining directly and take targeted samples from suspicious areas. Hysteroscopy catches focal lesions that blind sampling misses.
How Often Samples Come Back Insufficient
Sometimes the biopsy doesn’t collect enough tissue to read under a microscope, and the result comes back as “insufficient” or “inadequate for diagnosis.” This isn’t a diagnosis of anything wrong. It just means the lab couldn’t evaluate the sample. Among over 27,000 patients in one large study, the overall insufficiency rate was 12.1%. But your odds vary significantly by menopausal status.
Premenopausal patients had an insufficiency rate of 7.6%. Postmenopausal patients had a much higher rate of 29.1%, nearly one in three. This happens because the uterine lining thins considerably after menopause, leaving less tissue for the device to collect. An insufficient result typically means the biopsy needs to be repeated or followed up with a different procedure like hysteroscopy with D&C.
Pipelle vs. D&C
For years, D&C was considered the gold standard. It involves dilating the cervix and scraping tissue from the uterine walls under anesthesia. The Pipelle biopsy was developed as a less invasive office alternative, and the data shows it performs nearly as well. Sample adequacy was 97.6% for Pipelle versus 100% for D&C, a difference that wasn’t statistically significant. The agreement between the two methods was near-perfect, with a Cohen’s Kappa of 0.948.
The practical difference is patient experience. Pipelle biopsies are done in the office without anesthesia and take about a minute. Patients report pain scores of 5 to 7 on a 10-point scale during the procedure, comparable to strong menstrual cramps. D&C requires operating room time and sedation, but it collects a more complete sample. Both, however, share the same fundamental limitation: neither allows the doctor to see what they’re sampling.
Complications Are Rare
Endometrial biopsy is a low-risk procedure. The most serious potential complication, uterine perforation, occurs at a rate of roughly 0.8 to 6.4 per 1,000 procedures. For D&C specifically, perforation rates are about 0.3% in premenopausal women and 2.6% in postmenopausal women, whose uterine walls tend to be thinner. The Pipelle device is thinner and more flexible than D&C instruments, which makes perforation even less likely during office biopsies. Most complications, when they occur, involve temporary cramping or light bleeding that resolves within a day or two.
When Ultrasound Comes First
Before a biopsy is ordered, many doctors start with a transvaginal ultrasound to measure the thickness of the uterine lining. In postmenopausal women, a lining under 5 mm is generally considered normal. Thicknesses above 8 mm raise suspicion and typically prompt a biopsy, offering 83.6% sensitivity but only 56.4% specificity at that cutoff. Raising the threshold to 16 mm improves specificity to 75% but drops sensitivity to 67%, meaning more abnormalities get missed. The exact threshold that should trigger a biopsy is still debated, but ultrasound serves as a useful screening step to determine who needs tissue sampling.
Who Needs a Biopsy
Current guidelines recommend endometrial sampling for anyone 45 or older with abnormal uterine bleeding, since age is a significant risk factor for endometrial cancer. For younger patients, biopsy is indicated when there’s persistent bleeding, a history of unopposed estrogen exposure (estrogen without progesterone, which can overstimulate the lining), or when medical treatment hasn’t controlled the bleeding. The office Pipelle biopsy is the recommended first step. If the sample is inadequate, the procedure can’t be performed, or symptoms persist despite normal results, hysteroscopy with D&C is the next move.
What Your Results Mean in Practice
If your biopsy comes back showing cancer or precancerous changes, the result is highly reliable. False positives are exceedingly rare given the 99.8% specificity. You can trust an abnormal finding.
If your biopsy comes back normal but your symptoms continue, that’s worth taking seriously. A normal blind biopsy doesn’t guarantee the uterine lining is clear, especially if the concern involves a small or localized abnormality. The next step in that scenario is typically hysteroscopy, where the doctor can visually inspect the cavity and biopsy specific areas. Think of the Pipelle biopsy as an excellent first screening tool, but not the final word if something still doesn’t feel right.